UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a)
of the Securities Exchange Act of 1934
Filed by the Registrant [X]
Filed by a Party other than the Registrant
[ ]
Check the appropriate box:
|
[ ]
|
|
Preliminary Proxy Statement
|
|
[ ]
|
|
Confidential, for Use of the SEC Only (as permitted by
Rule 14a-6(e)(2))
|
|
[ ]
|
|
Definitive Proxy Statement
|
|
[X]
|
|
Definitive Additional Materials
|
|
[ ]
|
|
Soliciting Material Pursuant to 14a-12
|
VistaGen Therapeutics, Inc.
(Name of Registrant as Specified In Its Charter)
_________________________________
(Name of Person(s) Filing Proxy Statement, if other than the
Registrant)
Payment of Filing Fee (Check the appropriate box):
[X] No fee required.
[ ] Fee computed on table
below per Exchange Act Rules 14a-6(i)(4) and
0-11.
|
1.
|
|
Title of each class of securities to which transaction
applies:
|
|
2.
|
|
Aggregate number of securities to which transaction
applies:
|
|
3.
|
|
Per unit price or other underlying value of transaction computed
pursuant to Exchange Act Rule 0-11 (set forth the amount on
which the filing fee is calculated and state how it was
determined):
|
|
4.
|
|
Proposed maximum aggregate value of transaction:
|
|
5.
|
|
Total fee paid:
|
[ ] Fee paid
previously with preliminary materials.
[ ] Check box if any part
of the fee is offset as provided by Exchange Act
Rule 0-11(a)(2) and identify the filing for which the
offsetting fee was paid previously. Identify the previous filing by
registration statement number, or the Form or Schedule and the date
of its filing.
|
1.
|
|
Amount Previously Paid:
|
|
2.
|
|
Form, Schedule or Registration Statement No.:
|
|
3.
|
|
Filing Party:
|
|
4.
|
|
Date Filed:
|
Explanatory Note
VistaGen Therapeutics, Inc. (the
Company) is filing the attached proxy card as an
amendment to the DEF 14A that was filed with the Securities and
Exchange Commission on July 23, 2019, as the proxy card was
inadvertently omitted from the original filing. The proxy card has
been made available to the Company’s shareholders in the form
attached hereto.
